Teva's Progesterone Ring Passes Phase III Clinical Test

Study finds vaginal ring used weekly to supplement progesterone of in vitro fertilization patients is equally effective in getting them pregnant as daily vaginal gel.

Yoram Gabison
Yoram Gabison
Yoram Gabison
Yoram Gabison

A vaginal ring used once a week to supplement the progesterone of women undergoing in vitro fertilization is as effective in getting them pregnant as a vaginal gel that must be applied every day, according to the results of the Phase III clinical trial for the Milprosa vaginal ring, Milprosa manufacturer Teva Pharmaceutical Industries announced Monday.

The study found that clinical pregnancy rates at eight and 12 weeks were comparable for both groups, with slightly fewer than half the women undergoing treatment getting pregnant at each point. Almost all the patients pregnant at week 12, when progesterone treatment ended, went on to have a live birth: 97.4 percent for the Milprosa group and 96.5 percent for the vaginal gel group.

“The study results demonstrate that Milprosa may be an effective and safe option for progesterone supplementation during the luteal phase (the latter part of the menstrual cycle) among women undergoing IVF,” said Dr. Laurel Stadtmauer, who authored the study and is a professor of obstetrics and gynecology at Jones Institute for Reproductive Medicine at Eastern Virginia Medical School. “Since normal luteal function may be compromised among women undergoing IVF, progesterone supplementation is essential and the more options patients have, the better. If approved, the once-weekly dosing of Milprosa may offer convenience for patients.”

Teva said the safety rates were also comparable between the Milprosa group and the group using gel with an 8-percent progesterone level. Serious adverse events – most commonly including nausea, headache, abdominal or back pain and fatigue – occurred in approximately 12 percent of patients in both treatment groups.

The Phase III data has been published in the scientific journal Fertility and Sterility.

The randomized, single-blind study was conducted at 22 clinical sites in the United States and included 1,297 patients between the ages of 18 and 42. Of enrolled patients, 646 were randomized to Milprosa and 651 to the vaginal gel.

A doctor taking an ultrasound of a pregnant patient.Credit: Eliyahu Hershkovitz

Click the alert icon to follow topics:



Automatic approval of subscriber comments.

Subscribe today and save 40%

Already signed up? LOG IN


Election ad featuring Yair Lapid in Rahat, the largest Arab city in Israel's Negev region.

This Bedouin City Could Decide Who Is Israel's Next Prime Minister

Dr. Claris Harbon in the neighborhood where she grew up in Ashdod.

A Women's Rights Lawyer Felt She Didn't Belong in Israel. So She Moved to Morocco

Mohammed 'Moha' Alshawamreh.

'It Was Real Shock to Move From a Little Muslim Village, to a Big Open World'

From the cover of 'Shmutz.'

'There Are Similarities Between the Hasidic Community and Pornography’

A scene from Netflix's "RRR."

‘RRR’: If Cocaine Were a Movie, It Would Look Like This

Prime Minister Yair Lapid.

Yair Lapid's Journey: From Late-night Host to Israel's Prime Minister